Back to results
US 8,912,236 B2Granted
Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
AssigneeAlcon Research, Ltd.
InventorsBhagwati P. Kabra, Malay Ghosh, Adrian Sauceda
Life of this patent
Estimating the term…
Abstract
The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.
Claims7
A method for treating age-related macular degeneration in a patient in need thereof with a therapeautically effective amount of a multi-targeted receptor tyrosine kinase inhibitor comprising:
- heating an ophthalmic composition to its melting point to liquefy the ophthalmic composition, the ophthalmic composition comprising the multi-targeted receptor tyrosine kinase inhibitor in an amount of from 0.01% to 20% and polyethylene glycol having a molecular weight of at least 6000 in an amount from 40% to 98%;
- injecting into an eye of the patient the ophthalmic composition in liquid form after heating;
- and
- allowing the composition to cool in the eye of the patient causing the composition to solidify in the eye of the patient.
1 more element
Dependencies are inferred from the claim text.